Lung Cancer Cell Lines With Egfr Mutation

A systematic review and meta analysis.

Lung cancer cell lines with egfr mutation.

Lung cancer is one of the most frequent neoplasm worldwide and about 85 90 of lung cancer is non small cell lung cancer nsclc activating mutations in the kinase domain of epidermal growth factor receptor egfr in nsclc commonly arise as in frame deletions in exon 19 and l858r exon 21 base substitution and confer sensitivity to the reversible tyrosine kinase inhibitors. In the present study we found that nsclc cell lines with the epidermal growth factor receptor egfr gene mutations were more sensitive to x ray irradiation than those with wild type egfr p 0 05 no difference in radiosensitivity was observed between nsclc cells with egfr exon19 deletion del 19 mutation and exon 21 point mutation at position 858 l858r with or without t790m. Non small cell lung cancer nsclc is linked to a number of genetic mutations. Germline mutations in lung cancer.

Epidermal growth factor receptor egfr mutations are the second most common oncogenic driver event in non small cell lung cancer nsclc classical activating mutations exon 19 deletions and the l858r point mutation comprise the vast majority of egfr mutations and are well defined as strong predictors for good clinical response to egfr tyrosine kinase inhibitors egfri. Mutations of the epidermal growth factor receptor egfr gene have been identified in specimens from patients with non small cell lung cancer who have a response to anilinoquinazoline egfr. Reported a family with multiple cases of non small cell lung cancer nsclc associated with germline transmission of the egfr t790m mutation. Egfr mutation incidence in non small cell lung cancer of adenocarcinoma histology.

Midha a dearden s mccormack r. Egfr mutation frequency in middle east and african non small cell lung cancer patients. A systematic review and. The egfr t790m mutation was discovered as a secondary point mutation that causes a structural change in egfr and gefitinib resistance.